The melanocortin system, explained — tanning, libido, appetite, inflammation, all from one receptor family

This isn't a quirk of biology. It's architecture. And understanding how it works explains why so many peptide-based drugs — some approved, some experimental, some still in gray-market circulation — target different nodes of this system with very different clinical goals.

The whole cascade starts with a single gene: proopiomelanocortin, or POMC. The name sounds like a bureaucratic acronym, but it encodes something genuinely elegant. POMC is a precursor protein, meaning the body synthesizes it as a long chain and then cuts it into smaller active peptides depending on which tissue is doing the cutting and what enzymes are present. In the pituitary, POMC gets cleaved primarily into ACTH — the adrenocorticotropic hormone that drives cortisol production. In the hypothalamus and the skin, different enzymes cut POMC into alpha-MSH: alpha-melanocyte-stimulating hormone. It's alpha-MSH and its close relatives (beta-MSH, gamma-MSH) that are the primary endogenous ligands for the melanocortin receptors.

Alpha-MSH is a 13-amino-acid peptide. Small by protein standards — barely a peptide at all. But it binds with meaningful affinity to four of the five melanocortin receptors, which is why the effects of this system spread so far. The question is always: which receptor is being activated where, and what happens downstream?

The first melanocortin receptor, MC1R, is the one most people have heard of without knowing its name. It is expressed predominantly in melanocytes — the pigment-producing cells in your skin and hair follicles. When alpha-MSH binds MC1R, it activates a signaling cascade that upregulates tyrosinase, the rate-limiting enzyme in melanin synthesis. The result is increased production of eumelanin, the dark brown-black pigment that gives skin and hair their darker tones and, more importantly, absorbs and scatters UV radiation. This is the photoprotective function: melanin converts the energy of UV photons into heat rather than allowing it to reach DNA.

MC1R has natural variation in the human population that matters a great deal. Certain MC1R variants — called red hair color variants, colloquially — produce a receptor that responds poorly to alpha-MSH. People with two non-functional MC1R alleles tend to have red or very light hair, fair skin that tans minimally, and higher risk of UV-induced DNA damage and melanoma. This isn't just aesthetics. It's a functional difference in how well the signaling pathway works at the cellular level. The entire rationale for early melanocortin peptide drug development — the work coming out of the University of Arizona in the 1980s — rested on this observation: if you could pharmacologically stimulate MC1R more strongly than endogenous alpha-MSH does, you might provide photoprotection to people who can't generate enough of their own.

The second receptor, MC2R, is the most specialized. It binds only ACTH, not alpha-MSH, and it is expressed almost exclusively in the adrenal cortex. MC2R is the mechanism by which the pituitary drives cortisol synthesis — a critical node in the HPA axis that governs the stress response. Most drugs targeting the melanocortin system are designed to avoid this receptor, both because it requires a larger peptide ligand and because ACTH-mediated cortisol release is not what any of the current applications are trying to achieve.

The third and fourth receptors, MC3R and MC4R, are where things get interesting from a metabolic and neurological standpoint. Both are expressed centrally — in the hypothalamus, brainstem, and limbic structures — and both participate in the regulation of energy balance and body composition. MC4R in particular is one of the most studied obesity-related targets in pharmacology. Loss-of-function mutations in MC4R are the most common single-gene cause of severe early-onset obesity in humans, affecting roughly 1 in 2000 people. When MC4R signaling is intact and active, it suppresses appetite and increases energy expenditure. When it's knocked out, the result is hyperphagia and weight gain.

MC4R also mediates sexual function, and this is where the system produces one of its more surprising intersections. The same receptor that controls energy balance also plays a role in the initiation of sexual arousal — particularly, in the erectile and genital arousal response. This was not a theoretical deduction. It was discovered accidentally in the lab, which will be covered in detail in the Melanotan II origin article. But the mechanism involves central MC4R activation in hypothalamic circuits that project into autonomic pathways governing genital blood flow. This is how PT-141 (bremelanotide), a melanocortin peptide approved for hypoactive sexual desire disorder in women, works: it activates MC4R in the brain to initiate a sexual arousal response without acting directly on the vascular system the way phosphodiesterase inhibitors do.

MC3R has a partially overlapping role in energy balance but also participates in immune modulation. It is expressed in immune cells including macrophages and monocytes, and its activation tends to shift the inflammatory balance toward resolution. This is a consistent theme across the melanocortin system: several of the receptors, particularly MC3R and MC1R, have anti-inflammatory properties. Alpha-MSH itself was identified as a peripheral anti-inflammatory molecule before the receptor subtypes were fully characterized. It inhibits the production of pro-inflammatory cytokines and competes with some of the same downstream pathways as steroids, through different mechanisms. This property has driven research interest in melanocortin peptides for conditions like inflammatory bowel disease and sepsis, though none of these applications are approved.

The fifth receptor, MC5R, is the least studied of the family and the one with the narrowest expression pattern in many ways — though "narrow" is relative for a system this distributed. MC5R is expressed in exocrine glands, including sweat glands, sebaceous glands, and lacrimal glands, and it plays a role in regulating their secretory function. It also appears to be involved in lipid metabolism in peripheral tissues and has some immune function, though the clinical significance of MC5R modulation remains largely theoretical at this point. No drug has been developed specifically targeting MC5R.

The peptide drug landscape that has grown around this system reflects its breadth. Afamelanotide (Melanotan I) targets MC1R for tanning and photoprotection, approved for erythropoietic protoporphyria. Setmelanotide targets MC4R specifically for genetic obesity conditions including MC4R deficiency and POMC deficiency. Bremelanotide (PT-141) targets MC4R centrally for sexual dysfunction. KPV, a tripeptide fragment of alpha-MSH, is being researched for its anti-inflammatory properties at MC1R and MC3R in conditions affecting the gut. And Melanotan II, the most widely circulated peptide in online research communities, is a non-selective analog that hits MC1R, MC3R, MC4R, and MC5R simultaneously — which accounts for both its potent effects and its complicated side effect profile.

What this diversity of applications tells us is something important about how evolution builds. The melanocortin system is ancient — its core components are present in fish, insects, and even invertebrates in recognizable form. The ancestral version of the system appears to have coordinated pigmentation responses to light exposure, which in early organisms was a simple survival mechanism: produce pigment when UV is high, reduce it when UV is low. Over hundreds of millions of years of vertebrate evolution, that same signaling architecture got repurposed again and again. The same receptor subtypes that originally tuned melanin production got co-opted into energy sensing (you tan more in summer when food is abundant), then into reproductive signaling (reproduce when well-nourished), then into immune coordination (modulate inflammation via the same system that responds to external stressors like UV).

This is what biologists call pleiotropy — one gene or pathway with many phenotypic effects — and it is the norm in complex organisms rather than the exception. Evolution is constrained and opportunistic. When a signaling pathway exists and works, it tends to acquire new functions rather than being replaced. The melanocortin system is an extreme example: a single family of ligands, derived from one precursor, acting through five receptors to coordinate functions as diverse as pigmentation and appetite. Understanding this architecture doesn't just explain how the drugs work. It explains why touching one part of this system so reliably produces effects in the others — and why drugs targeting these receptors always carry the possibility of off-target consequences that seem, at first glance, completely unrelated to the intended effect.

The breadth of the system is a feature. It is also, from a pharmacological standpoint, the central challenge.